StaClear Low-Particulate Ophthalmic Syringe Launches New CE Marking at Medica

Meet StaClear at Medica

Düsseldorf, Germany | November 17–20, 2025

Hall 16 / F11-1 | USA Pavilion – North Carolina Section

StaClear, manufacturer of the low-particulate ophthalmic syringe that recently received its CE marking, will exhibit at MEDICA 2025, the world’s leading medical trade fair

Why StaClear Is Coming to MEDICA

MEDICA attracts over 80,000 healthcare professionals from around the world — from pharmaceutical executives and hospital pharmacists to device engineers and distributors. StaClear’s decision to exhibit in Düsseldorf marks a pivotal moment for ophthalmic innovation and beyond.

“When patients trust surgeons with their eyesight, every detail matters,” said Vinay Sakhrani, CEO of StaClear. “Syringes designed for general use aren’t good enough for the eye. We build the ones that are.”

1️⃣ Wet AMD Is a Global Challenge

Intravitreal injections are performed worldwide, yet most syringes were never engineered for ocular use. StaClear designs syringes specifically for ophthalmic precision in three ways: 1. Minimizing particulates to meet USP 789, 2. Reducing dead volume to save on drug wastage, and 3. Ophthalmic safe materials with better dosing accuracy

2️⃣ Pharma Companies Need Smaller, Cleaner Syringes

High-value intravitreal injections, biologics, pediatric formulations, and specialized injectables demand smaller volumes and reduced particulate generation. StaClear delivers both.

3️⃣ Now CE Marked and Ready for Europe

With CE certification achieved, StaClear is actively vetting European distribution and pharmaceutical partnerships.

4️⃣ Technology for Medical Device OEMs

StaClear’s proprietary low-particulate coating benefits any precision device — from insulin pumps to cardiac delivery systems. The company offers contract manufacturing services for partners seeking cleaner, smoother syringe or component performance. Whether in cardiology, oncology, diabetes, or pediatrics, particulates compromise safety and performance.

Who Will Benefit From Meeting StaClear at MEDICA?

Compounding /Hospital Pharmacies preparing intravitreal injections
Pharmaceutical Companies manufacturing ophthalmic or pediatric injectables
Medical Device OEMs looking for a contract manufacturing partner
Distributors serving retina and specialty pharmaceutical markets
Quality Assurance Teams investigating particulate-related complications or looking for small form factor syringes

The StaClear Difference

Low Sub-Visible Particulate Levels - every lot tested for USP 789.
Low dead volume for costly drugs.
Smooth plunger action for precision injections.
Smaller form factor preferred by doctors.

Visit StaClear at MEDICA 2025

Location: Hall 16, Booth F-11-1 (USA Pavilion, North Carolina Section)

Dates: November 17–20, 2025

Contact: Vinay Sakhrani, CEO – StaClear: Use our contact form to schedule a time to meet.

MEDICA Exhibitor Profile: StaClear MEDICA 2025 Listing

Advance meetings are available for qualified distributors, pharma companies, and device OEMs. To secure a slot, contact info@staclear.com or send a request via our contact form before November 15.

PLEASE NOTE: Limited availability due to high demand.

About StaClear

StaClear manufactures low-particulate syringes designed for ophthalmic injection. StaClear syringes worked with ophthalmologists, compounding pharmacists, and pharmacuetical companies to optimize the smaller form factor, glidability, and other features to their needs. Headquartered in North Carolina, USA, StaClear combines precision engineering with advanced materials science to minimize risk.

Mission: To protect patient outcomes by perfecting the devices clinicians trust for drug delivery.

Media Contact:

Neesha Mirchandani

Director of Communicates, StaClear

info@staclear.com or send a request via our contact form.

Exhibitor Data Sheet